PDCD1 and colorectal carcinoma: ICIs directed against PD-1/PD-L1 and CTLA-4 have been applied in CRC therapy, yielding marked efficacy in patients with DNA mismatch repair (dMMR) deficiency or microsatellite instability-high (MSI-H) tumors.